COMPUGROUP MEDICAL AG sees a downgrade to Neutral on account of less fundamental stars
The independent financial analyst theScreener just lowered the general evaluation of COMPUGROUP MEDICAL AG (DE), active in the Software industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date June 9, 2020, the closing price was EUR 66.75 and its target price was estimated at EUR 54.26.CompuGroup Medical develops and sells software as well as information technology services for the healthcare sector. Co. is engaged in the development of e-health solutions. Co.'s software products and services are designed to support medical activities in doctors' offices, medical laboratories, pharmacies, hospitals and other provider organizations. Co. serves a range of healthcare providers, from general practitioners, community clinics and pharmacies, to hospitals and medical laboratories. Co.'s segments includes: Ambulatory Information Systems; Pharmacy Information Systems; Hospital Information Systems; Communication & Data; Workflow & Decision Support; and Internet Service Provider.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.